Cargando…
Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients
About 60% of RA patients don’t achieve good response with biological disease-modifying anti-rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi’s). Previously, a link between TNFα and interleukin (IL)-32 was reported in RA. However, the exact mechanism linking IL-32 to response to treat...
Autores principales: | Damen, Michelle S. M. A., Schraa, Kiki, Tweehuysen, Lieke, den Broeder, Alfons A., Netea, Mihai G., Popa, Calin D., Joosten, Leo A. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145899/ https://www.ncbi.nlm.nih.gov/pubmed/30232372 http://dx.doi.org/10.1038/s41598-018-32485-0 |
Ejemplares similares
-
Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018) -
bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017) -
Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study
por: Bouman, Chantal A M, et al.
Publicado: (2018) -
IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis
por: Damen, Michelle S. M. A., et al.
Publicado: (2017) -
Identification of Discriminating Metabolic Pathways and Metabolites in Human PBMCs Stimulated by Various Pathogenic Agents
por: Zhang, Xiang, et al.
Publicado: (2018)